杨森制药的厄达替尼在医保范围内吗？

(Erdafitinib) is an FGFR inhibitor. FGFRs are a family of receptor tyrosine kinases that can be activated by genetic mutations in many types of tumors, thereby promoting the survival and proliferation of tumor cells. The drug works by targeting genetic mutations in FGFR. The drug, developed by Xi'an Janssen Pharmaceutical Co., Ltd., represents the first treatment option for patients with metastatic bladder cancer harboring mutations in the FGFR gene.

Xi'an Janssen is currently China's largest joint venture pharmaceutical company and the largest OTC product company in the industry. It owns many well-known OTC brands and is committed to the development and introduction of specialized prescription drug products, making each specialized product a leader in related fields. Over the past 23 years, the company has maintained sustained and stable development and has become China's leading joint venture pharmaceutical company. So far, it has ranked first among pharmaceutical companies in China for 13 consecutive years. In the 2006 list of the top 100 pharmaceutical companies in China, Xi'an Janssen ranked first among foreign pharmaceutical companies with sales of $3.412 billion.

The U.S. Food and Drug Administration (FDA) granted Janssen Pharmaceuticals' erdafitinib Breakthrough Therapy designation for the treatment of urothelial cancer in March 2018; on September 18, 2018, Janssen Biotech notified the U.S. FDA After submitting a new drug application, the FDA accelerated the approval of erdafitinib on April 12, 2019. The tablet is sold under the trade name Balversa®. The drug is mainly used in clinical trials to treat adult patients with locally advanced or metastatic urothelial cancer whose disease has progressed after receiving platinum-based chemotherapy.

Although Janssen Pharmaceuticals has been on the market abroad for more than a year, it has also brought great help to the treatment of many patients. However, it is regrettable that the drug has not yet been able to enter the Chinese market, so it cannot be included in the scope of medical insurance.

Recommended hot articles: /newsDetail/96462.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.